Blunted Fas signaling favors RIPK1-driven neutrophil necroptosis in critically ill COVID-19 patients

Autor: Tiziano A. Schweizer, Markus Huemer, Hoeller S, Annelies S. Zinkernagel, Hitz E, Chun-Chi Chang, Baum J, Mairpady Shambat S, Holger Moch, Hertegonne S, Reto A. Schuepbach, Alejandro Gómez-Mejia, Daniel A. Hofmaenner, Silvio D. Brugger, Clément Vulin, Claudio T. Acevedo, Philipp K. Buehler

Critically ill COVID-19 patients are characterized by a severely dysregulated cytokine profile and elevated neutrophil counts, which are thought to contribute to disease severity. However, to date it remains unclear how neutrophils contribute to path

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b19157b33afbd33f45fb99866eb4e5e0
https://doi.org/10.1101/2021.03.19.436166

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Hyperinflammatory environment drives dysfunctional myeloid cell effector response to bacterial challenge in COVID-19.

Autor: Mairpady Shambat S; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Gómez-Mejia A; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Schweizer TA; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Huemer M; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Chang CC; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Acevedo C; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Bergada-Pijuan J; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Vulin C; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Hofmaenner DA; Institute of Intensive Care, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Scheier TC; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Hertegonne S; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Parietti E; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Miroshnikova N; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Wendel Garcia PD; Institute of Intensive Care, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Hilty MP; Institute of Intensive Care, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Buehler PK; Institute of Intensive Care, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Schuepbach RA; Institute of Intensive Care, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Brugger SD; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Zinkernagel AS; Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Publikováno v: PLoS pathogens [PLoS Pathog] 2022 Jan 10; Vol. 18 (1), pp. e1010176. Date of Electronic Publication: 2022 Jan 10 (Print Publication: 2022).